NervGen Pharma Statistics
Total Valuation
NervGen Pharma has a market cap or net worth of $204.83 million. The enterprise value is $143.72 million.
| Market Cap | 204.83M |
| Enterprise Value | 143.72M |
Important Dates
The next estimated earnings date is Saturday, November 14, 2026, before market open.
| Earnings Date | Nov 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NervGen Pharma has 107.52 million shares outstanding. The number of shares has increased by 13.43% in one year.
| Current Share Class | 107.52M |
| Shares Outstanding | 107.52M |
| Shares Change (YoY) | +13.43% |
| Shares Change (QoQ) | +14.75% |
| Owned by Insiders (%) | 2.07% |
| Owned by Institutions (%) | 13.90% |
| Float | 95.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 16.71 |
| P/TBV Ratio | 17.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.23
| Current Ratio | 1.23 |
| Quick Ratio | 1.19 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -757.48% and return on invested capital (ROIC) is -245.96%.
| Return on Equity (ROE) | -757.48% |
| Return on Assets (ROA) | -37.70% |
| Return on Invested Capital (ROIC) | -245.96% |
| Return on Capital Employed (ROCE) | -186.97% |
| Weighted Average Cost of Capital (WACC) | 8.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.36M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.72% in the last 52 weeks. The beta is 0.82, so NervGen Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -18.72% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 3.24 |
| Relative Strength Index (RSI) | 42.78 |
| Average Volume (20 Days) | 490,810 |
Short Selling Information
The latest short interest is 5.49 million, so 5.11% of the outstanding shares have been sold short.
| Short Interest | 5.49M |
| Short Previous Month | 5.44M |
| Short % of Shares Out | 5.11% |
| Short % of Float | 5.76% |
| Short Ratio (days to cover) | 9.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.75M |
| Pretax Income | -43.63M |
| Net Income | -43.63M |
| EBITDA | -22.71M |
| EBIT | -22.75M |
| Earnings Per Share (EPS) | -$0.64 |
Balance Sheet
The company has $61.12 million in cash and no debt, with a net cash position of $61.12 million or $0.57 per share.
| Cash & Cash Equivalents | 61.12M |
| Total Debt | n/a |
| Net Cash | 61.12M |
| Net Cash Per Share | $0.57 |
| Equity (Book Value) | 12.17M |
| Book Value Per Share | 0.11 |
| Working Capital | 11.90M |
Cash Flow
| Operating Cash Flow | -18.02M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 39,209 |
| Net Borrowing | -41,373 |
| Free Cash Flow | -18.02M |
| FCF Per Share | -$0.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NervGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -13.43% |
| Shareholder Yield | -13.43% |
| Earnings Yield | -21.24% |
| FCF Yield | -8.78% |
Analyst Forecast
The average price target for NervGen Pharma is $11.08, which is 481.63% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.08 |
| Price Target Difference | 481.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |